Clovis Oncology Inc. (NASDAQ:CLVS) was upgraded by Vetr from a “sell” rating to a “buy” rating in a report released on Monday. The brokerage currently has a $39.27 target price on the biopharmaceutical company’s stock. Vetr‘s target price points to a potential upside of 9.82% from the stock’s current price.
CLVS has been the topic of a number of other research reports. SunTrust Banks Inc. increased their price objective on Clovis Oncology from $38.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, September 23rd. Piper Jaffray Cos. reissued a “neutral” rating and set a $42.00 price objective on shares of Clovis Oncology in a report on Wednesday, October 12th. Zacks Investment Research cut Clovis Oncology from a “buy” rating to a “hold” rating in a report on Tuesday, October 4th. Credit Suisse Group AG restated an “outperform” rating and issued a $41.00 target price on shares of Clovis Oncology in a research note on Monday, October 10th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $45.00 target price on shares of Clovis Oncology in a research note on Monday, October 17th. One analyst has rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the stock. Clovis Oncology has a consensus rating of “Hold” and an average target price of $36.41.
Shares of Clovis Oncology (NASDAQ:CLVS) traded down 8.00% during mid-day trading on Monday, hitting $34.39. The stock had a trading volume of 1,840,050 shares. The stock’s market cap is $1.33 billion. Clovis Oncology has a 12 month low of $11.57 and a 12 month high of $40.29. The firm has a 50 day moving average price of $32.24 and a 200-day moving average price of $22.69.
Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.95) by $0.25. During the same period in the previous year, the firm posted ($2.62) EPS. On average, equities research analysts forecast that Clovis Oncology will post ($8.97) EPS for the current year.
Large investors have recently modified their holdings of the stock. Alps Advisors Inc. boosted its stake in shares of Clovis Oncology by 25.1% in the second quarter. Alps Advisors Inc. now owns 53,924 shares of the biopharmaceutical company’s stock valued at $740,000 after buying an additional 10,828 shares in the last quarter. Fox Run Management L.L.C. bought a new stake in shares of Clovis Oncology during the second quarter valued at $154,000. State Board of Administration of Florida Retirement System boosted its stake in shares of Clovis Oncology by 8.0% in the second quarter. State Board of Administration of Florida Retirement System now owns 22,819 shares of the biopharmaceutical company’s stock valued at $313,000 after buying an additional 1,693 shares in the last quarter. Boxer Capital LLC bought a new stake in shares of Clovis Oncology during the second quarter valued at $6,174,000. Finally, Quantitative Systematic Strategies LLC bought a new stake in shares of Clovis Oncology during the second quarter valued at $751,000.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.